Instituto de Investigacion Sanitaria La Fe

Quick facts

Marketed products

• A (Chloraprep) · Infection Prevention / Dermatology
  Chloraprep is an antimicrobial skin antiseptic that kills bacteria and other microorganisms on the skin surface through oxidative damage.
• B (Clorhexidine 2%) · Infectious Disease / Antisepsis
  Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects.
• Bravelle · Other

Phase 3 pipeline

• Ganirelix 0.25 mg. · Reproductive Medicine / Fertility
  Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion to prevent premature ovulation during assisted reproductive procedures.
• Micronized natural progesterone. · Gynecology / Reproductive Health
  Micronized natural progesterone binds to progesterone receptors throughout the body to exert hormonal effects on the endometrium, breast, and other reproductive tissues.
• Recombinant choriogonadotropin alfa · Reproductive Medicine / Fertility
  Recombinant choriogonadotropin alfa (hCG) is a recombinant human chorionic gonadotropin that stimulates ovarian follicle development and triggers final oocyte maturation in assisted reproductive technology.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Instituto de Investigacion Sanitaria La Fe portfolio CI brief
• Instituto de Investigacion Sanitaria La Fe pipeline updates RSS

Frequently asked questions about Instituto de Investigacion Sanitaria La Fe

Related

• A (Chloraprep) · Infection Prevention / Dermatology
• B (Clorhexidine 2%) · Infectious Disease / Antisepsis
• Bravelle · Other
• Sector hub: All tracked pharma companies